Evolus Inc (EOLS)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
EOLS
Evolus Inc
$6.67
+1.06%
HEALTHCARE · Cap: $439.25M
TAK
Takeda Pharmaceutical Co Ltd ADR
$15.60
+0.97%
HEALTHCARE · Cap: $49.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 1492894% more annual revenue ($4.51T vs $301.79M). TAK leads profitability with a 4.3% profit margin vs -14.4%. TAK earns a higher WallStSmart Score of 57/100 (C).
EOLS
Avoid30
out of 100
Grade: F
TAK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+71.0%
Fair Value
$14.83
Current Price
$6.67
$8.16 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -18730.0% — below average capital efficiency
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
4.3% margin — thin
Operating margin of 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : EOLS
The strongest argument for EOLS centers on Debt/Equity.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bear Case : EOLS
The primary concerns for EOLS are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 42.5x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
EOLS profiles as a turnaround stock while TAK is a value play — different risk/reward profiles.
EOLS carries more volatility with a beta of 1.33 — expect wider price swings.
EOLS is growing revenue faster at 6.7% — sustainability is the question.
EOLS generates stronger free cash flow (-10M), providing more financial flexibility.
Bottom Line
TAK scores higher overall (57/100 vs 30/100). EOLS offers better value entry with a 71.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evolus Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evolus, Inc., a high-performance beauty company, provides aesthetic medical products for physicians and their patients in the United States. The company is headquartered in Newport Beach, California.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?